PHARMING GRP EO-,01

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
N69603145
SEDOL
B9CPS12
CIK
N/A
pharming.com
LEI:
©
FIGI: BBG000BM1LJ0
PHARM
PHARMING GRP EO-,01
GICS: 35201010 · Sector: Kidney drugs · Sub-Sector: -
NAME
PHARMING GRP EO-,01
ISIN
NL0010391025
TICKER
PHARM
MIC
XAMS
REUTERS
PHAR.AS
BLOOMBERG
PHARM NA
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 29.10.2024

Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 29.10.2024 / 14:51 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclu...
Research & Analysis
Read more
Mon, 26.08.2024

Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 26.08.2024 / 15:55 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclu...
Research & Analysis
Read more
Wed, 09.08.2023

Original-Research: Pharming Group NV - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Group NV Unternehmen: Pharming Group NV ISIN: NL0010391025 Anlass der Studie: Q2 2023 results Empfehlung: Buy seit: 09.08.2023 Kursziel: €1.60 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: ...
Research & Analysis
Read more
Tue, 18.07.2023

Original-Research: Pharming - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Unternehmen: Pharming ISIN: NL0010391025 Anlass der Studie: Update Empfehlung: Buy seit: 18.07.2023 Kursziel: €1.50 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Simon Scholes First Berlin Equity Re...
Research & Analysis
Read more
Tue, 18.07.2023

Original-Research: Pharming - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Unternehmen: Pharming ISIN: NL0010391025 Anlass der Studie: Update Empfehlung: Buy seit: 18.07.2023 Kursziel: €1.50 Kursziel auf Sicht von: 12 months Letzte Ratingänderung: - Analyst: Simon Scholes First Berlin Equity Re...
Research & Analysis
Read more
Tue, 04.08.2020

Original-Research: Pharming Group NV - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Pharming Group NV Unternehmen: Pharming Group NV ISIN: NL0010391025 Anlass der Studie: Q2-Ergebnisse Empfehlung: Kaufen seit: 04.08.2020 Kursziel: €1,80 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: - Analyst:...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements